Valeant Pharma (NYSE: VRX) announced the addition of G. Mason Morfit, President of ValueAct Capital, to its board of directors ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hedge Funds Hot Corp. News Hot Mgmt Changes Management Changes Management Comments Trader Talk

Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-DateOctober 26, 2015 7:28 AM Valeant Pharma (VRX) Releases Slides Ahead of Investor Conference CallOctober 26, 2015 7:28 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharma (VRX) Says Philidor Accounting is AppropriateOctober 26, 2015 6:16 AM Form 10-Q Valeant Pharmaceuticals For: Sep 30October 26, 2015 6:07 AM Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of DirectorsOctober 26, 2015 6:00 AM